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Abstract 
Purpose: Statins represent an effective treatment for hyperlipidaemia. Immune-mediated 
necrotising myopathy (IMNM), a form of statin myopathy, has recently been described, and is 
characterized by elevated creatine kinase, presence of antibodies against HMG-CoA and no 
improvement after drug discontinuation, even with immunosuppressive treatment. Information 
on IMNM is mainly from case reports and small case series. Therefore, all reported cases of 
IMNM in VigiBase, the WHO global database of individual case safety reports (ICSRs) 
including the underlying reporting patterns were analysed to characterize more detailed this 
adverse drug reaction. 
Methods: ICSRs of IMNM up to October 1st, 2016 were extracted from VigiBase. 
Corresponding case narratives were requested from responsible national authorities to 
maximize the available data. The reports were analysed in terms of reporting criteria, co-
reported terms, patient demographics, clinical data, administered medication, latency time, 
seriousness of the reaction and outcome.  
Results: 101 deduplicated ICSRs of IMNM were reported until October 2016 from 17 countries. 
Approximately two third of the cases were from the year 2016. Slightly more males than 
females were affected (52 [57%] males vs. 39 [42%] females). Median reported patient age was 
68 years (range 16 – 87 years). 91 cases (99%) were classified as serious. Median latency time 
was 26 months (range 1 – 288 months). Median creatine kinase value was 6,860 U/L (range 
576 – 35,000 U/L). In total, 8 patients (9%) had recovered from IMNM.  Atorvastatin was the 
most frequently reported statin in 80 % of cases. 
Conclusions: The number of IMNM reports has increased in recent years. IMNM associated 
with statin treatment seems to occur worldwide. Most IMNM cases were reported with 
atorvastatin. No dose dependency of statin-associated IMNM pathogenesis was identified. 
Keywords: HMG-CoA-reductase inhibitors, rosuvastatin, atorvastatin, pravastatin, simvastatin, 
muscle pain, immunosuppression, CK elevation, creatinine-kinase, HMG-CoA antibody
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Introduction 
 
Clinical evidence in statin therapy is robust, and medical experts and guidelines recommend 
this drug class as first-line therapy for the primary and secondary prevention of cardiovascular 
disease in patients with dyslipidaemia [1, 2]. However, statin intake can be associated with 
adverse drug effects that can lead to discontinuation. Among these effects, musculoskeletal 
adverse drug reactions (ADRs) are the most common [3], with a wide spectrum related to statin 
use, ranging from non-severe muscle pain with or without laboratory findings to serious 
complications such as rhabdomyolysis. Statin myopathy is typically self-limiting, resolving 
after treatment discontinuation [4].  
Approximately 2–3 out of every 100,000 patients treated with statins develop a necrotizing 
autoimmune myopathy (IMNM) with the presence of autoantibodies against 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase (anti-HMG-CoA) [5]. Anti-HMG-CoA 
autoantibodies are directed against the catalytic domain of HMG-CoA, a protein located in the 
membrane of the endoplasmic reticulum which is involved in cholesterol biosynthesis and 
inhibited by statins [6]. On the other hand anti-HMG-CoA autoantibodies can be detected in 
statin-naïve patients, indicating this autoimmune condition can also occur in the absence of 
statin exposure [6, 7]. 
Patients with IMNM experience myalgia with symmetrical and proximal weakness. Laboratory 
tests may reveal substantially elevated (>2000 U/L in approximately 90% of cases; normal 
range <171 U/L) creatine kinase (CK) concentrations [5, 8]. Myopathy might be progressive, 
even after the discontinuation of statin therapy [5], and represents the main clinical feature 
which leads to suspicion of an autoimmune myopathy. Treatment options of IMNM include 
immediate administration of high-dose corticosteroids, other immunosuppressive agents and 
intravenous immunoglobulins [9]. 
The Swiss Agency of Therapeutic Products notified health professionals of the new risks 
associated with statin therapy [10].  
Given the lack of larger case series, cohort studies and other studies with broader impact 
regarding this ADR, we analysed all registered cases of IMNM as well as the associated 
reporting patterns from VigiBase, the World Health Organization (WHO) global database of 
individual case safety reports (ICSRs) to better characterize this uncommon ADR of statins. 
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Methods 
 
ICSRs with a reported ADR term corresponding to MedDRA preferred term “Immune-
mediated necrotising myopathy” was selected as the VigiBase search criterion with an entry 
date up to October 1st 2016. This preferred term includes the lower-level terms “Immune-
mediated necrotising myopathy” and “Immune-mediated necrotizing myopathy”. All ICSRs 
contained at least one suspected statin, other cases were excluded from the study. 
 
VigiBase is the largest global collection of ICSRs. More than 110 countries around the world 
report ADRs to the WHO Uppsala Monitoring Center (UMC) through their national 
pharmacovigilance centres (NPVCs) [11]. At national level, health-care professionals (HCPs), 
pharmaceutical companies and, in some countries, consumers report ADRs to the responsible 
NPVC. VigiBase primarily collects spontaneous, post-marketing reports to enable the earliest 
possible detection of ADRs and also allows data collection according to WHO Anatomical 
Therapeutic Chemical classification [12, 13]. The following details were extracted from the 
UMC database: patient age and gender, completeness information - indicating how detailed 
an ICSR was filled in and representing data quality [14], reporting country, reporter 
qualification, ADR seriousness, indication, drug dosage and treatment dates, route of 
administration, onset of reaction, adverse reaction and patient outcome. The seriousness 
criteria in VigiBase are “Death”,” Life-threatening”, “Caused and prolonged hospitalization”, 
“Disabling/Incapacitating” and “Other”, which are also part of ICH E2A criteria.  
To obtain a maximum of information for each ICSR, all competent authorities were requested 
to deliver corresponding case narratives which are not available in VigiBase. Subsequently, 74 
narratives from 9 countries were received, and included information on patient demographics 
(age at ADR onset and gender), seriousness of ICSR, laboratory values (e.g. CK, antibodies), 
administered drugs, dosages, duration of treatment, onset date, outcome and latency time, which 
was defined as the time between starting of medication and diagnosis. Individual ICSR case 
narratives were also reviewed to identify duplicate cases. Where no corresponding case 
narrative was available, duplicates were identified via the following characteristics: patient age 
and gender, reported ADR terms and reported medication.  
Where the month and year (MM.YYYY) of the start, stop or onset date were reported, we 
considered the recorded month as a full month (30 days). Where only the year (YYYY) was 
reported, we counted the recorded year as a full year (365 days). In case of discrepancies 
between the narrative and the initial coded information, we recoded the data according to the 
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case narrative. Where two or more statins were administered, the dosage of the last reported 
statin was used for analysis. Pearson’s correlation was used for comparing statin doses and CK 
values, which as well as autoantibody detection data were extracted from the narratives for 
analysis.  
Where unspecific antibodies, besides IMNM pathognomic HMG-CoA antibodies [5], were 
documented and CK values were within the normal reference range, the respective case was 
excluded from the study. Reports without antibody and CK value information were included in 
the study. The frequency of administration of concomitant medications was also analysed, as 
well as the co-reported ADR terms. 
For descriptive analyses, Microsoft Office Excel (2010) and IBM SPSS Statistics (version 23) 
for Windows were used. 
 
Results 
 
Until October 2016 overall a total of 13.799.728 ICSRs were archived in VigiBase, of which 
159 international ICSRs with the preferred term for IMNM were extracted (Figure 1). Of these, 
32% were reported between 2012 and 2015 while 68% were from 2016. Fifty-eight reports 
were excluded as duplicates. One case was excluded because it reported nonspecific antibodies 
that were not pathognomic for IMNM. In eight cases, no statin use was reported. The remaining 
92 reports, from 17 countries (Australia, Belgium, Canada, Czech Republic, France, Germany, 
Greece, Hungary, Italy, Japan, the Netherlands, Norway, Slovenia, Spain, Sweden, Switzerland 
and the United States), were used for further analysis. Most reports came from the United States 
(29%).The overall patient characteristics and those of two subgroups, representing cases from 
Europe and North America, are presented in Table 1. The cases within these subgroups were 
found to differ in reporter qualification (Figure 2). Although 52% of European cases were 
reported by physicians, only 7% of North American cases were reported in this way.  
The overall median age of patients was 68 years (range 16 – 87 years) (Table 1).  
Overall, slightly more males than females were affected by IMNM incidence (52 [57%] males 
vs 39 [42%] females; for 1 case, gender was unknown).  In Europe, slightly more cases were 
reported for females than for males, 59 vs 41.The majority of reports (91 [99%]) were classified 
as serious (Figure 1, Table 1).  
Median latency time between start of medication and diagnosis for all 92 cases was 26 months 
(range 1 – 288) (Table 1).  
The overall median CK value was elevated, at 6,860 U/L (range 576–35,000 U/L) (Table 1).  
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HMG-CoA antibody testing was documented in approximately one third of cases. A positive 
result was obtained in over 70% of these cases (Table 1).  
 
In total, 8 patients (9%) recovered from IMNM (Table 1).  
 
Table 2 displays the type and number of reported statins, the most frequently reported 
concomitant medications, as well as the top co-reported terms. Atorvastatin was the most 
frequently coded statin in 80% of the cases, followed by simvastatin (26%), rosuvastatin (19%) 
and pravastatin (3%). The median daily atorvastatin dose was 40 mg (range 5–80 mg) for a 
median time of 36 weeks (range 1–232 weeks). The median daily doses for simvastatin and 
pravastatin were 40 mg, while median rosuvastatin intake was 20 mg. There was no correlation 
between administered statin dose and CK value (Pearson’s correlation coefficient 0.073, p = 
0.722 for cases with 1 statin; and −0.108, p = 0.753 for two or more statins). 
The most frequent concomitant medication was ezetimibe (18 patients [20%]), followed by 
metformin (11 [12%]), acetylsalicylic acid (10 [11%]), levothyroxine (9 [10%]) and amlodipine 
(8 [9%]).  
In two patients (2%), co-administration of amlodipine and simvastatin was documented. Most 
frequent co-reported terms were polymyositis and blood creatine phosphokinase increased 
(each 10% of the patients) followed by myopathy (9%), rhabdomyolysis (7%) and asthenia 
(5%). 
 
Discussion 
 
Statin-associated IMNM seems to be a global reported phenomenon with reports worldwide. In 
our analysis this recently characterized autoimmune disease predominantly occurred in Europe 
and North America, while only a few reports came from Asia and Australia. Since 32% of our 
cases were reported between 2012 and 2015 and 68% resulted of reports in 2016, it became 
obvious that the number of reports increased distinctly. This circumstance might not have been 
attributed to a higher incidence of the underlying disease in such a short period rather than an 
increased awareness of the diagnosis “statin-associated IMNM”. Possibly an increased 
awareness of the diagnosis IMNM has led to an increased willingness to report these cases.  
Nevertheless in this study the number of European and North American reports were the same 
they differentiated from their reporter qualification. 52% of European cases were reported by 
physicians, only 7% of North American cases were reported this way. A possible explication 
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for differences in reporting qualifications might be the existence of “physician assistants” (PAs) 
in the United States, which reported most of our cases (29%) [15]. The PAs are semi-
autonomous clinicians practicing in partnership with physicians, performing also diagnosis and 
diagnostic testing [15]. PAs are increasingly valuable reporters to pharmacovigilance systems 
[16]. These reports classified as ICSRs from “other health professionals” in VigiBase could 
have been co-responsible of the increasing incidence of North American reports.  
 
In the present study, the administration of atorvastatin, simvastatin and pravastatin implicated 
in the development of IMNM was in line with previous studies [17, 18, 19]. However, almost 
one in five patients in our cohort were treated with rosuvastatin before being diagnosed with 
IMNM, which diverges the findings of other studies. Moreover, only 3% of patients with 
IMNM were treated with pravastatin in our study. 
 
Atorvastatin and simvastatin, which exhibit similar pharmacological properties in terms of 
lipophilicity and metabolization via CYP3A4 [20], which possibly could predispose to develop 
IMNM, were the most frequently reported statins. In contrast, rosuvastatin and pravastatin, 
which are hydrophilic substances are only partly metabolized in the liver via phase II reactions. 
Both exhibit minor or no metabolism via the CYP pathway [21].  
Higher numbers of IMNM cases related to a specific statin might also be dependent of 
prescription habits. 
In parts of Canada, the country which reported 19% of our ICSRs, at least, atorvastatin is the 
most frequently prescribed statin [22]. Most reports (29%) from VigiBase were derived from 
the United States, where simvastatin prescriptions were twice as frequent as atorvastatin 
prescriptions within the period 2003–2012 [23]. Even if atorvastatin prescription has increased 
in the United States in recent years, the high proportion of statin-associated IMNM reports 
related to atorvastatin is difficult to explain through prescribing practices alone.  
In our analysis, most patients (80%) with IMNM had previously received atorvastatin. This 
phenomenon was also observed in the study of Grable-Esposito et al. where 21 of 25 patients 
(84%) with diagnosis of Statin-associated IMNM were exposed to atorvastatin [19]. In the study 
of Troyanov et al. from 14 patients diagnosed with statin-associated IMNM, 12 (86%) had 
previously taken atorvastatin [22]. In a recent published case series from New Zealand, all 4 
included patients with the same diagnosis were also previously on atorvastatin [24]. Even 
though there is some evidence for an increased rate of IMNM cases associated with atorvastatin 
administration, a class effect of statins cannot be excluded also based on our data. 
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The administered dose range for all statins was within the approved therapeutic dosage range.  
In our investigation higher doses of statins were not associated with higher CK values. While 
dose dependency for the self-limited form of statin myopathy has been established [17, 25], 
such a relationship cannot be confirmed for myopathies with an autoimmune background [26] 
also based on our data. 
 
Based on our data, the effect of concomitant medications that potentially interact with statins 
on the risk for IMNM remains unclear. Pharmacokinetically relevant interactions between statin 
use and the most frequently co-administrated drugs (ezetimibe, metformin, acetylsalicylic acid 
and levothyroxine) were not identified. However, the co-administration of amlodipine 10 
mg/day has been shown to increase the simvastatin plasma–concentration–time curve (AUC) 
by 77% for the risk of adverse effects in muscle [27]. Whether this interaction is clinically 
relevant for IMNM remains questionable based on our data. 
 
Most frequent co-reported terms (polymyositis, blood creatine phosphokinase increased, 
myopathy, rhabdomyolysis and asthenia) are associated with muscular disorders. Terms of 
other organ systems were coded infrequently, assuming that other conditions only played a 
negligible role.  
 
Most cases in the present study were classified as serious, some with life-threatening, disabling 
or fatal outcomes. These findings support the medical relevance of IMNM and impaired quality 
of life experience by affected patients. Previous studies have shown that IMNM patients were 
older than 50 years [5, 17, 28], which is in line with the median age of 68 years in our cohort. 
A recent review described 100 IMNM patients with an average age of 65 years [29]. Males and 
females were almost equally affected, a finding similar to other studies [27, 30].  
The median latency time between starting of medication and diagnosis in our cohort was 26 
months, with a broad range. The duration of statin exposure required to develop IMNM has 
been reported as an average of 2–3 years [18, 31], which is consistent with our data.  
 
The average CK concentration of 6,860 U/L (normal values: up to 170 U/L in women and 190 
U/L in men) with a broad range (576–35,000 U/L) is comparable to previous reports [17, 29].  
HMG-CoA antibodies are often, but not necessarily, found in patients with statin-associated 
IMNM. [17]. Nowadays new diagnostic tests have been established to confirm the diagnosis of 
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anti-HMG-CoA positive IMNM, which are now commercially available [32].  Therefor a 
biopsy is no more required to confirm the diagnosis of IMNM in case of a positive HMG-CoA 
antibody result, but remains necessary to establish diagnosis of antibody-negative IMNM [33]. 
In our patient cohort, HMG-CoA antibody testing was documented for 32 patients, 23 (72%) 
of whom had a positive test result. This percentage of positive test results has already been 
observed in another investigation [34]. 
 
Limitations 
 
This study was based on spontaneously reported ICSR on statin-associated IMNM. 
Underreporting, missing data and duplicate cases are well-known issues for this type of report. 
For completion, we requested corresponding case narratives from respective competent 
authorities in 16 countries to increase the available information for each case. Nevertheless 
there is still some information missing. We were thus better able to detect duplicate cases and 
increase the quality of data in our analysis. Considering that approximately one third (36%) of 
the cases were eliminated as duplicates, this constitutes an important issue in 
pharmacovigilance databases, especially in very rare adverse drug reactions. We cannot totally 
exclude the possibility of any other duplicates. Data in VigiBase and also in the case narratives 
are anonymized. Moreover, they do not contain the exact treatment information for each IMNM 
patient and we could not detail on diagnostic or therapeutic procedures due to missing 
information.  In cases, where results from biopsy or antibody testing were not documented to 
assure diagnosis of statin-associated IMNM, other explanations cannot be totally excluded, 
although an implied causality of spontaneous reports based on the suspicion of the reporter is 
usually present. On the other hand there could be reports describing symptoms that could be 
classified as IMNM, but which are not diagnosed and coded accordingly. This would 
presumably lead to missed cases. Moreover, health systems differentiate on an international 
level. Therefore, the comparability of reporter qualifications concerning ADR reporting may 
be limited.  
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Conclusion 
 
Where muscle pain persists despite the discontinuation of HMG-CoA reductase inhibitors, 
physicians should consider an autoimmune cause alongside established self-limiting statin-
associated myopathies. The number of IMNM reports has increased in recent years. Statin-
associated IMNM does not seem to be a dose-dependent phenomenon. A class effect of statins 
cannot be excluded. Most IMNM cases were associated with the substance atorvastatin. Further 
studies are needed to clarify specific factors of this rare adverse drug reaction.  
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Figure 1 Flow Chart of VigiBase Analysis 
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Figure 2 ICSR Distribution – Reporter Qualification by Continent 
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Table 1       Demographic Data – Seriousness - Latency – Test Results- Outcome 
 All Cases 
(n=92) 
European Cases 
(n=44) 
North American 
Cases 
(n=44) 
Characteristics Number % Number % Number % 
Age at onset (years)      
Median 68 68 68 
Range 16  -  87 55  -  87 33  -  81 
Sex       
Female 39 42 26 59 11 25 
Male 52 57 18 41 32 73 
Unknown 1 1 0 0 1 2 
Seriousness Criteria       
Death 1 1 0 0 1 2 
Life threatening 6 7 5 11 0 0 
Caused/prolonged - 
Hospitalization 
31 34 23 52 7 16 
Disabling/incapacitation 7 8 7 16 0 0 
Other 63 68 23 52 40 91 
Completeness Score       
Median 0.36 0.55 0.32 
Range 0.1  -  1 0.22  -  1 0.1  -  0.63 
Latency (months)    
Median 26 25 38 
Range 1  -  288 1  -  288 1  -  243 
Creatine Kinase (U/l)       
Median 6860 6000 7913 
Range 576  -  35000  1344  -  28572 576  -  35000 
HMG-CoA Antibodies       
Test documented 32  20  11  
Positive 23 72 14 70 9 82 
Outcome       
Fatal 1 1 0 0 1 2 
Recovered 8 9 7 16 1 2 
Not recovered 9 10 5 11 2 5 
Recovered with sequelae 6 7 5 11 0 0 
Recovering 26 28 15 34 11 25 
Unknown 42 46 12 27 29 66 
3 Australian and 1 Japanese case were not included in analyses by continent 
Latency: time between starting of medication and diagnosis 
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Table 2 Drugs and co-reported reactions 
 
 All cases 
(n = 92) 
Statin 
coded/patient 
Number %  
One 69 75  
Two 20 22  
Three or more 3 3  
Statins 
administered 
  Daily dose (mg) Duration of intake 
(months) 
  Median Range  Median Range 
Atorvastatin 74 80 40 5.00–80 36 1–232 
Simvastatin  24 26 40 10.00–80 31 1–168 
Rosuvastatin 17 19 20 1.25–40 13 1–114 
Pravastatin 3 3 40 40.00–40  n.a. n.a. 
Top 5 concomitant medication  
Ezetemib 18 20  
Metformin 11 12  
Acetylsalicylic 
acid 
10 11  
Levothyroxine 9 10  
Amlodipine 8 9  
Top 5 Co-reported terms  
Polymyositis 9 10  
Blood creatine 
phosphokinase 
increased  
9 10  
Myopathy 8 9  
Rhabdomyolysis 6 7  
Asthenia 5 5  
n.a. = not available 
 
